Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
SRT2019
SRT2019 Oct. 4 at 6:30 PM
$AFMD
1 · Reply
SRT2019
SRT2019 Oct. 4 at 3:48 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Oct. 3 at 7:48 PM
$AFMD web site.. https://www.affimed.com/about-us/scientific-advisory-board/
3 · Reply
deathknight
deathknight Oct. 3 at 11:54 AM
$AFMD btw, just found out yesterday that Leland, Muller and Harstrick all retired from Affimed NV's board on September 5th. Only Wolfgang Fischer remains. There's no public announcement or even LinkedIn updates of their position change, so they likely stay on the payroll. Pretty unusual but could be inline with RTO scenario.
1 · Reply
deathknight
deathknight Oct. 2 at 11:44 PM
$AFMD The subsidiary is clearly undergoing an asset sale, but how about the parent? Are we going to see a reverse take over, since it's publicly traded? If selling the subsidiary can actually generate some significant cash, RTO would be very attractive to private companies -- let's not forget Gilde is a major sharesholder of the parent and it has tons of portfolio companies need to become public for the VC to successfully exit.
1 · Reply
Hodl707
Hodl707 Oct. 2 at 5:10 PM
$AFMD so if the preliminaries have started for GHMB AFMD.. then aren’t we a little anxious to find out? I mean, AFMD.NV still need to go to it proceedings and is that when we’re gonna find out? If anything has sold.
2 · Reply
Hodl707
Hodl707 Sep. 30 at 8:13 PM
$AFMD
1 · Reply
deathknight
deathknight Sep. 30 at 2:01 PM
$AFMD It has been more than 4 months since anything made public by the company. Definitely a very frustrating and nerve breaking silence.
1 · Reply
Think_Bigly
Think_Bigly Sep. 29 at 11:32 PM
Roche happy to pay $AFMD $5B over time. The Q is.. how much discount to take out now? 90%-92% should be enough. -'Terry Chrisomalis, writing for Seeking Alpha, notes, “In my opinion, the amount of cash given to Affimed pretty much validates its technology. This deal is expected to close by Q3 in 2018 customary to certain closing conditions. There have only been a few deals in the past that have amounted to a $5 billion milestone payment for a biotech. What that tells me is that Roche really wants to get its hands on Affimed’s Redirected Optimized Cell Killing (ROCK) platform.'
1 · Reply
Hodl707
Hodl707 Sep. 29 at 12:55 PM
$AFMD with so many NK pipelines failing! And with and with the rock platform and its IP’s having such great data, could this be? I mean a great opportunity to get picked up
1 · Reply
Latest News on AFMD
No data available.
SRT2019
SRT2019 Oct. 4 at 6:30 PM
$AFMD
1 · Reply
SRT2019
SRT2019 Oct. 4 at 3:48 PM
$AFMD
0 · Reply
Think_Bigly
Think_Bigly Oct. 3 at 7:48 PM
$AFMD web site.. https://www.affimed.com/about-us/scientific-advisory-board/
3 · Reply
deathknight
deathknight Oct. 3 at 11:54 AM
$AFMD btw, just found out yesterday that Leland, Muller and Harstrick all retired from Affimed NV's board on September 5th. Only Wolfgang Fischer remains. There's no public announcement or even LinkedIn updates of their position change, so they likely stay on the payroll. Pretty unusual but could be inline with RTO scenario.
1 · Reply
deathknight
deathknight Oct. 2 at 11:44 PM
$AFMD The subsidiary is clearly undergoing an asset sale, but how about the parent? Are we going to see a reverse take over, since it's publicly traded? If selling the subsidiary can actually generate some significant cash, RTO would be very attractive to private companies -- let's not forget Gilde is a major sharesholder of the parent and it has tons of portfolio companies need to become public for the VC to successfully exit.
1 · Reply
Hodl707
Hodl707 Oct. 2 at 5:10 PM
$AFMD so if the preliminaries have started for GHMB AFMD.. then aren’t we a little anxious to find out? I mean, AFMD.NV still need to go to it proceedings and is that when we’re gonna find out? If anything has sold.
2 · Reply
Hodl707
Hodl707 Sep. 30 at 8:13 PM
$AFMD
1 · Reply
deathknight
deathknight Sep. 30 at 2:01 PM
$AFMD It has been more than 4 months since anything made public by the company. Definitely a very frustrating and nerve breaking silence.
1 · Reply
Think_Bigly
Think_Bigly Sep. 29 at 11:32 PM
Roche happy to pay $AFMD $5B over time. The Q is.. how much discount to take out now? 90%-92% should be enough. -'Terry Chrisomalis, writing for Seeking Alpha, notes, “In my opinion, the amount of cash given to Affimed pretty much validates its technology. This deal is expected to close by Q3 in 2018 customary to certain closing conditions. There have only been a few deals in the past that have amounted to a $5 billion milestone payment for a biotech. What that tells me is that Roche really wants to get its hands on Affimed’s Redirected Optimized Cell Killing (ROCK) platform.'
1 · Reply
Hodl707
Hodl707 Sep. 29 at 12:55 PM
$AFMD with so many NK pipelines failing! And with and with the rock platform and its IP’s having such great data, could this be? I mean a great opportunity to get picked up
1 · Reply
Hodl707
Hodl707 Sep. 26 at 8:51 PM
$AFMD Roche acquired Poseida for approximately $1 billion upfront, with potential for up to $500 million more, to gain Poseida's proprietary donor-derived, allogeneic cell therapy platform and its pipeline of treatments for cancers and autoimmune diseases. The acquisition allows Roche to expand into the promising allogeneic cell therapy field, build its capabilities in this area, and progress unique, potentially best-in-class therapies across oncology, immunology, and neurology.
2 · Reply
deathknight
deathknight Sep. 26 at 4:15 PM
$AFMD The white-blue W shape logo belongs to WordPress -- a website designer/hoster. I was wrong to suggest it's a "new" logo for Affimed. That being said, while Roche is not using WordPress, their subsidiary Poseidas Therapeutics is using the company.
2 · Reply
deathknight
deathknight Sep. 26 at 2:14 PM
$AFMD If you type in their website address, you can see they are using a new logo (in the address bar). It's a W shaped white-blue theme logo -- the color theme matches all Roche subsidiaries. We need official confirmation but there's definitely something happening.
1 · Reply
deathknight
deathknight Sep. 26 at 1:28 PM
$AFMD Think about it, Affimed's NKCE and TCE combined with Poseida's Allogenic NK cells and T cells with solid proof of concept. The efficacy could easily match ANY existing CAR-T and outperform first line cancer therapies with much better safety profile and yet CHEAPER! The distribution can be seamlessly integrated with Roche's existing logistics. This will give Roche a dominant advantage in the cancer therapeutic field.
0 · Reply
deathknight
deathknight Sep. 26 at 1:21 PM
$AFMD I bet that Roche did bite after all. There may be a new Affimed as Roche subsidiary which combined with Poseida will be the corner stone for Roche's future off-the-shelf and plug-in ready oncology solution. If so this likely can explain why most (64 out of 75) of their employees have stayed.
0 · Reply
deathknight
deathknight Sep. 26 at 1:18 PM
$AFMD Their website is showing a brand new design and in "maintenance mode will be available soon" -- and it shows Affimed 2025. Something IS COMING!! You'd never see a company about to die to get itself a new website.
0 · Reply
Hodl707
Hodl707 Sep. 26 at 4:23 AM
$AFMD what if
4 · Reply
Hodl707
Hodl707 Sep. 25 at 6:04 AM
$AFMD https://www.quiverquant.com/news/Affimed+N.V.+Reports+Positive+Findings+on+AFM24%27s+Exposure-Outcome+Analysis+in+Refractory+Non-Small+Cell+Lung+Cancer+Patients
0 · Reply
Think_Bigly
Think_Bigly Sep. 24 at 11:38 PM
$AFMD Good or not, this is a new day for Affi.. imo.
0 · Reply
deathknight
deathknight Sep. 23 at 6:50 PM
$AFMD Just found that MD Anderson have their collaboration study using AFM13 published earlier this year: https://www.nature.com/articles/s41591-025-03640-8 I don't have access to the full paper but nature medicine is considered one of the best journals and this publication should be sufficient to clear any doubts of the data quality -- at least for AFM13.
1 · Reply
deathknight
deathknight Sep. 23 at 2:26 PM
$AFMD From what I learned about insolvency case history of Tobias Wahl, our administrator, it likely no deal will be announced before the first creditor's meeting. If there's a deal, we probably can hear something in Oct/Nov not before.
3 · Reply
Hodl707
Hodl707 Sep. 19 at 10:05 PM
$AFMD hmm .006 is that a glitch
2 · Reply